Barrow Hanley Mewhinney & Strauss LLC Alkermes Plc. Transaction History
Barrow Hanley Mewhinney & Strauss LLC
- $28.9 Billion
- Q3 2024
A detailed history of Barrow Hanley Mewhinney & Strauss LLC transactions in Alkermes Plc. stock. As of the latest transaction made, Barrow Hanley Mewhinney & Strauss LLC holds 618 shares of ALKS stock, worth $17,520. This represents 0.0% of its overall portfolio holdings.
Number of Shares
618
Previous 636
2.83%
Holding current value
$17,520
Previous $15,000
13.33%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ALKS
# of Institutions
358Shares Held
181MCall Options Held
168KPut Options Held
96.6K-
Black Rock Inc. New York, NY29.1MShares$825 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA19MShares$538 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD13MShares$369 Million0.04% of portfolio
-
Wellington Management Group LLP Boston, MA12.7MShares$359 Million0.06% of portfolio
-
State Street Corp Boston, MA9.19MShares$260 Million0.01% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $4.66B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...